American Healthcare Capital is pleased to offer a unique opportunity to invest in a high performance, visionary media publisher poised to disrupt the cancer community. The company is revolutionizing patient engagement at the moment it matters most. They are an 8x award-winning specialty publisher delivering a more personalized education experience to individuals newly diagnosed with cancer—while helping oncology-related brands earn early and lasting consideration.
The platform’s unique design offers oncology related brands, operating in an increasingly competitive environment, a highly efficient opportunity to reach and build awareness with patients and caregivers early in their cancer journey.
Pharma and wellness companies have already invested marketing dollars on the platform to increase brand awareness. The platform continues to gain momentum within the life science and cancer communities and anticipates accelerated growth as a growing number of potential sponsors look for proven, high quality media opportunities.
Unlike any other platform, this company is built around two high-margin business areas:
1. Precision Audience + “No Waste” Sponsorships
Leveraging a data-centric approach, they guarantee high-intent, pre-treatment exposure to cancer patients and caregivers at the most critical point in their journey: right before treatment decisions are made. Their next-gen learning experience simplifies complex diagnoses, enables side-by-side FDA-approved treatment comparisons, and equips users with cancer-type-specific questions to ask their care teams. For sponsors, it means zero wasted impressions and unmatched brand alignment.
2. Clinical Trial Reach & Enrollment
A proprietary audience development engine and immersive educational tools help hospitals and pharmaceutical companies recruit hard-to-reach clinical trial participants—faster and more cost-effectively. This offering accelerates enrollment every step of the process with precision targeting and meaningful engagement.
A Market Ripe for Disruption
Despite medical advances, U.S. cancer diagnoses are expected to surpass 2 million annually by 2025. This surge will coincide with an unprecedented wave of oncology drug launches and an intensely competitive media landscape—where early brand consideration will be more critical than ever.
This organization is uniquely positioned to lead in this next era of oncology engagement.
Following the success of its first sponsorships in 2023, the company is now scaling rapidly and entering a strategic capital raise to fuel growth. The owner is looking for strategic investors with senior-level relationships within the pharma/cancer center/health media communities. The owner is seeking an investment of $1.5 million to $2 million to scale the business and build a direct sales organization and a robust marketing platform to accelerate growth.
